<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003602</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000066675</org_study_id>
    <secondary_id>RHG-AML97</secondary_id>
    <secondary_id>EU-98031</secondary_id>
    <nct_id>NCT00003602</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>A Randomised Study Comparing an Oral Regimen (Idarubicin and Etoposide) With an Intravenous Regimen (MAE) for Consolidation in Patients Over 55 Years With Acute Myeloid Leukaemia in First Complete Remission</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Riverside Haematology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more cancer cells. It is&#xD;
      not yet known which combination chemotherapy regimen is more effective in treating older&#xD;
      patients with acute myeloid leukemia.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of two different combination&#xD;
      chemotherapy regimens in treating older patients with acute myeloid leukemia in first&#xD;
      remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Compare the efficacy of oral idarubicin and etoposide vs intravenous mitoxantrone,&#xD;
           etoposide, and cytarabine as consolidation therapy in patients over 55 years old with&#xD;
           acute myeloid leukemia in first complete remission.&#xD;
&#xD;
        -  Compare the toxicity of these 2 regimens in these patients.&#xD;
&#xD;
        -  Assess the quality of life of these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Patients are stratified according to number of courses&#xD;
      of induction therapy required to achieve complete remission.&#xD;
&#xD;
      All patients receive induction chemotherapy consisting of idarubicin IV on days 1-3 and&#xD;
      cytarabine IV over 12 hours on days 1-7. Patients receive 1-2 courses of induction&#xD;
      chemotherapy to achieve complete remission.&#xD;
&#xD;
      Patients are randomized to one of two treatment arms for consolidation therapy after&#xD;
      achieving complete remission.&#xD;
&#xD;
        -  Arm I: Patients receive 2 courses of mitoxantrone IV on days 1 and 2, etoposide IV over&#xD;
           1 hour on days 1-5, and cytarabine IV over 12 hours on days 1-5.&#xD;
&#xD;
        -  Arm II: Patients receive 2 courses of oral idarubicin and etoposide on days 1-3.&#xD;
&#xD;
      Quality of life is assessed before each course of consolidation chemotherapy and 6-8 weeks&#xD;
      after completion of therapy.&#xD;
&#xD;
      Patients are followed until death.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 400 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 1998</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cytarabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>idarubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mitoxantrone hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed de novo or secondary acute myeloid leukemia (AML)&#xD;
&#xD;
               -  Prior myelodysplasia allowed&#xD;
&#xD;
               -  Refractory anemia with excess blasts (RAEB) OR&#xD;
&#xD;
               -  RAEB in transformation&#xD;
&#xD;
          -  No relapsed AML&#xD;
&#xD;
          -  No chronic granulocytic leukemia in transformation&#xD;
&#xD;
          -  No CNS disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 55&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  Transaminases no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 2.5 times ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No severe or uncontrolled cardiac failure&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No serious medical, social, or psychological condition&#xD;
&#xD;
          -  Not HIV 1 or 2 seropositive&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No plan for future autograft&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior chemotherapy for myelodysplastic syndrome or AML&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specifed&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No concurrent aluminum or magnesium-based antacids&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Graham Jackson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Newcastle-upon-Tyne Hospitals NHS Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Newcastle Upon Tyne Hospitals NHS Trust</name>
      <address>
        <city>Newcastle-Upon-Tyne</city>
        <state>England</state>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2001</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>untreated adult acute myeloid leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Idarubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

